Equities Analysts Set Expectations for GANX FY2025 Earnings

Gain Therapeutics, Inc. (NASDAQ:GANX) – Equities research analysts at Roth Capital raised their FY2025 earnings per share estimates for Gain Therapeutics in a note issued to investors on Wednesday, November 12th. Roth Capital analyst B. Pachaiyappan now expects that the company will post earnings per share of ($0.64) for the year, up from their previous estimate of ($0.69). Roth Capital has a “Buy” rating and a $6.00 price target on the stock. The consensus estimate for Gain Therapeutics’ current full-year earnings is ($1.00) per share. Roth Capital also issued estimates for Gain Therapeutics’ Q4 2025 earnings at ($0.14) EPS, Q1 2026 earnings at ($0.13) EPS, Q2 2026 earnings at ($0.13) EPS, Q3 2026 earnings at ($0.16) EPS, Q4 2026 earnings at ($0.20) EPS and FY2026 earnings at ($0.62) EPS.

GANX has been the topic of a number of other research reports. BTIG Research reissued a “buy” rating and issued a $9.00 price objective on shares of Gain Therapeutics in a report on Wednesday, October 15th. HC Wainwright reiterated a “buy” rating and set a $8.00 price target on shares of Gain Therapeutics in a research note on Monday, October 13th. Maxim Group upped their price objective on Gain Therapeutics from $5.00 to $7.00 and gave the stock a “buy” rating in a research note on Tuesday, October 7th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Gain Therapeutics in a report on Wednesday, October 8th. Seven research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $7.86.

Gain Therapeutics Stock Down 5.4%

NASDAQ:GANX opened at $2.83 on Monday. The company has a debt-to-equity ratio of 0.05, a quick ratio of 2.52 and a current ratio of 2.52. The firm has a market cap of $102.56 million, a P/E ratio of -4.64 and a beta of 0.13. Gain Therapeutics has a fifty-two week low of $1.41 and a fifty-two week high of $3.06. The firm has a 50-day simple moving average of $1.94 and a two-hundred day simple moving average of $1.83.

Gain Therapeutics (NASDAQ:GANX) last issued its quarterly earnings data on Wednesday, November 12th. The company reported ($0.15) EPS for the quarter, meeting the consensus estimate of ($0.15).

Institutional Trading of Gain Therapeutics

Several large investors have recently added to or reduced their stakes in the company. Dauntless Investment Group LLC purchased a new stake in shares of Gain Therapeutics in the first quarter valued at about $240,000. Marshall Wace LLP increased its position in Gain Therapeutics by 41.0% in the 2nd quarter. Marshall Wace LLP now owns 276,433 shares of the company’s stock valued at $498,000 after acquiring an additional 80,407 shares during the period. Kovitz Investment Group Partners LLC purchased a new stake in Gain Therapeutics during the 1st quarter valued at approximately $91,000. Squarepoint Ops LLC acquired a new stake in Gain Therapeutics during the 3rd quarter worth approximately $68,000. Finally, Virtu Financial LLC grew its stake in shares of Gain Therapeutics by 126.9% in the 3rd quarter. Virtu Financial LLC now owns 54,008 shares of the company’s stock valued at $96,000 after purchasing an additional 30,207 shares during the last quarter. Hedge funds and other institutional investors own 11.97% of the company’s stock.

About Gain Therapeutics

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.